Novabay Pharmaceuticals (NBY) |
|
1.01 0.054 (5.65%)
|
08-13 16:00 |
|
Open: |
0.95 |
Pre. Close: |
0.956 |
|
High:
|
1.04 |
Low:
|
0.925 |
|
Volume:
|
1,524,926 |
Market Cap:
|
42M |
|
|
|
|
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.042 - 1.049 |
1.049 - 1.056 |
|
Low:
|
0.914 - 0.922 |
0.922 - 0.93 |
|
Close:
|
0.997 - 1.01 |
1.01 - 1.023 |
|
Technical analysis |
as of: 2020-08-13 4:36:37 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.81 One year: 2.27 |
| Support: |
Support1: 0.92 Support2: 0.77 |
| Resistance: |
Resistance1: 1.55 Resistance2: 1.94 |
| Pivot: |
1.18  |
| Moving Average: |
MA(5): 1.05 MA(20): 1.23
MA(100): MA(250): 0.76 |
| MACD: |
MACD(12,26): -0.03 Signal(9): 0.01 |
| Stochastic oscillator: |
%K(14,3): 9.82 %D(3): 8.31 |
| RSI: |
RSI(14): 41.29 |
| 52-week: |
High: 1.94 Low: 0.24 Change(%): 40.3 |
| Average Vol(K): |
3-Month: 546946 10-Days: 331310 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.NBY has closed above bottom band by 17.3%. Bollinger Bands are 7.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 13 Aug 2020
Why Do Investors Care About NovaBay Pharmaceuticals, Inc. (NBY) - The News Heater
Sun, 09 Aug 2020
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha
Thu, 06 Aug 2020
NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results - Yahoo Finance
Thu, 06 Aug 2020
Are Shares Of NovaBay Pharmaceuticals, Inc. (NBY) Really Worth? - Invest Million
Mon, 03 Aug 2020
Gear up for the change! NovaBay Pharmaceuticals Inc. (NBY) has hit the volume of 1392532 - The InvestChronicle
Wed, 29 Jul 2020
NovaBay Pharmaceuticals Inc. (NBY) is heading in the right direction with an average volume of $5.31M - News Daemon
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE American |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
33 |
| Shares Float (M) |
17 |
|
% Held by Insiders
|
41.27 |
|
% Held by Institutions
|
6.53 |
|
Shares Short (K)
|
249 |
|
Shares Short P. Month (K)
|
377 |
Stock Financials |
|
EPS
|
-0.323 |
|
EPS Est This Year
|
-0.470 |
|
EPS Est Next Year
|
-0.090 |
|
Book Value (p.s.)
|
-0.010 |
|
Profit Margin
|
-100.14 |
|
Operating Margin
|
-93.82 |
|
Return on Assets (ttm)
|
-43.0 |
|
Return on Equity (ttm)
|
-1807.9 |
|
Qtrly Rev. Growth
|
30.5 |
|
Gross Profit (p.s.)
|
0.146 |
|
Sales Per Share
|
0.211 |
|
EBITDA (p.s.)
|
-0.196 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-6 |
|
Levered Free Cash Flow (M)
|
-2 |
Stock Valuations |
|
PE Ratio
|
-3.13 |
|
PEG Ratio
|
|
|
Price to Book value
|
-101.00 |
|
Price to Sales
|
4.79 |
|
Price to Cash Flow
|
-6.05 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
